<p>A, B: Tumour volumes recorded by calliper measurements of PC9 (A) and A549 tumours (B) pre- and post-carboplatin treatment as indicated. Data shown are mean ± SD of % volume compared to baseline (<i>n</i> = 4). *, <i>P</i><0.05; **, <i>P</i><0.01. C, D: Representative axial PET-CT images (30–60 min summed activity) for PC9 (C) and A549 (D) tumours. Tumour margins, indicated from CT image, are outlined in red. Mean ± SD (<i>n</i> = 4–6 animals per group). E, F: The tumour TAC representing average counts from a dynamic 60-minute scan for PC9 (E) and A549 xenografts (F) following carboplatin treatment (vehicle, 24 h or 48 h carboplatin-treated; <i>n = </i>4–6 animals per group).</p
<p>A: Carboplatin-induced growth inhibition in PC9 and A549 cells using a sulforhodamine B assay 72 ...
<p>(<b>a</b>) Growth in tumor volume was quantified by caliper measurements. Tumor progression was s...
<p>(A) Graph shows average tumor volumes amongst the treatment groups over the course of the experim...
<p>FLT uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=6 tumors...
<p>FDG uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=8 tumors...
<p>The intensities of all voxels within the tumour ROIs were computed and expressed as histogram plo...
F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of ...
<p>Images of [<sup>18</sup>F]FDG and [<sup>18</sup>F]FLT scans of representative MDA-MB-468 xenograf...
A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment o...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
<p>A) The eight images at left are representative coronal fused PET/CT images of two mice scanned wi...
<p>(A) Representative ZR-75-1 tumors were imaged using PET/CT with <sup>18</sup>F-FES on days 0, 3, ...
Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian canc...
<p><b>A:</b> Illustration of weekly bioluminescent image analysis of representative group of xenogra...
<p>A: Carboplatin-induced growth inhibition in PC9 and A549 cells using a sulforhodamine B assay 72 ...
<p>(<b>a</b>) Growth in tumor volume was quantified by caliper measurements. Tumor progression was s...
<p>(A) Graph shows average tumor volumes amongst the treatment groups over the course of the experim...
<p>FLT uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=6 tumors...
<p>FDG uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=8 tumors...
<p>The intensities of all voxels within the tumour ROIs were computed and expressed as histogram plo...
F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of ...
<p>Images of [<sup>18</sup>F]FDG and [<sup>18</sup>F]FLT scans of representative MDA-MB-468 xenograf...
A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment o...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
<p>A) The eight images at left are representative coronal fused PET/CT images of two mice scanned wi...
<p>(A) Representative ZR-75-1 tumors were imaged using PET/CT with <sup>18</sup>F-FES on days 0, 3, ...
Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian canc...
<p><b>A:</b> Illustration of weekly bioluminescent image analysis of representative group of xenogra...
<p>A: Carboplatin-induced growth inhibition in PC9 and A549 cells using a sulforhodamine B assay 72 ...
<p>(<b>a</b>) Growth in tumor volume was quantified by caliper measurements. Tumor progression was s...
<p>(A) Graph shows average tumor volumes amongst the treatment groups over the course of the experim...